Literature DB >> 15958811

Bortezomib for myeloma -- much ado about something.

Angela Dispenzieri.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15958811     DOI: 10.1056/NEJMe058059

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  6 in total

Review 1.  The role of ubiquitination in tumorigenesis and targeted drug discovery.

Authors:  Lu Deng; Tong Meng; Lei Chen; Wenyi Wei; Ping Wang
Journal:  Signal Transduct Target Ther       Date:  2020-02-29

Review 2.  The 26S proteasome complex: an attractive target for cancer therapy.

Authors:  Sarah Frankland-Searby; Sukesh R Bhaumik
Journal:  Biochim Biophys Acta       Date:  2011-10-18

3.  Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esophageal, gastric, and gastroesophageal cancer: phase II results from the North Central Cancer Treatment Group (N044B).

Authors:  Aminah Jatoi; Shaker R Dakhil; Nathan R Foster; Cynthia Ma; Kendrith M Rowland; Dennis F Moore; Anthony J Jaslowski; Sachdev P Thomas; Mark D Hauge; Patrick J Flynn; Philip J Stella; Steven R Alberts
Journal:  J Thorac Oncol       Date:  2008-05       Impact factor: 15.609

4.  Subcutaneous bortezomib might be standard of care for patients with multiple myeloma: a systematic review and meta-analysis.

Authors:  Ziqi Ye; Jie Chen; Zixue Xuan; Wenchao Yang; Jing Chen
Journal:  Drug Des Devel Ther       Date:  2019-05-16       Impact factor: 4.162

Review 5.  Multiple Myeloma Outpatient Transplant Program in the Era of Novel Agents: State-of-the-Art.

Authors:  Massimo Martino; Annalisa Paviglianiti; Mara Memoli; Giovanni Martinelli; Claudio Cerchione
Journal:  Front Oncol       Date:  2020-11-11       Impact factor: 6.244

Review 6.  The role of ubiquitination in tumorigenesis and targeted drug discovery.

Authors:  Lu Deng; Tong Meng; Lei Chen; Wenyi Wei; Ping Wang
Journal:  Signal Transduct Target Ther       Date:  2020-02-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.